抗血管内皮生长因子药物治疗眼内肿瘤及其并发症的研究进展  

Research advances on anti-vascular endothelial growth factor in the treatment of intraocular tumors and its complications

作　　者：狄宇 叶俊杰[1] Di Yu;Ye Junjie(Department of Ophthalmology,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院眼科,北京100730

出　　处：《中华眼底病杂志》2022年第10期857-861,共5页Chinese Journal of Ocular Fundus Diseases

摘　　要：眼内肿瘤是一种严重的致盲性眼病,其不仅损害患者视力,甚至还可危及患者生命。目前主要的治疗方法包括手术治疗、放射治疗、化学药物治疗、激光治疗或多种治疗方法联合。近年来随着抗血管内皮生长因子(VEGF)药物在眼科疾病治疗中的广泛应用,已有较多研究证实抗VEGF药物在眼内肿瘤及其并发症的治疗中发挥重要的辅助作用。在治疗眼内肿瘤的疗效方面,抗VEGF药物联合其他方法治疗脉络膜转移癌和视网膜母细胞瘤预后较好,而对葡萄膜黑色素瘤的治疗效果仍存在一定争议;在治疗眼内肿瘤并发症方面,抗VEGF药物对脉络膜骨瘤继发性病变及放射性视网膜病变也具有良好的治疗效果。在药物安全性上,抗VEGF药物局部给药可显著降低全身化学药物治疗的毒副作用。但目前研究中对抗VEGF药物治疗眼内肿瘤及其并发症的药物剂量和用药方案尚未统一,未来仍需进一步行基础与临床试验进行探索。Intraocular tumors is a serious blinding eye disease,which has a serious impact on patients'vision and even life.At present,the main treatments include surgical treatment,radiation therapy,chemotherapy,laser therapy and combination therapy.In recent years,with the wide application of anti-vascular endothelial growth factor(VEGF)in the treatment of ocular diseases,many studies have confirmed that anti-VEGF drugs play an important auxiliary role in the treatment of intraocular tumors and its complications.In terms of the therapeutic effect,intravitreal anti-VEGF combined with other methods have a good prognosis in the treatment of choroidal metastatic carcinoma and retinoblastoma,while the therapeutic effect of uveal melanoma is still controversial.In the treatment of intraocular tumor complications,intravitreal anti-VEGF also has a good effect on the secondary lesions of choroidal osteoma and radiation retinopathy.As for drug safety,intravitreal anti-VEGF can significantly reduce the toxic and side effects of systemic chemotherapeutic therapy.However,the dosage and medication regimen of anti-VEGF drugs in the treatment of intraocular tumors and their complications have not been unified in current studies,and further basic and clinical trials are still needed to explore in the future.

关 键 词：血管生成抑制剂 脉络膜肿瘤 葡萄膜肿瘤 黑色素瘤 视网膜母细胞瘤 综述 

分 类 号：R739.7[医药卫生—肿瘤]